Tailored Dosimetry Improves Treatment Outcomes in Hepatocellular Carcinoma with Yttrium-90 Resin Microsphere Radioembolization

1

Transarterial radioembolization (TARE) with Yttrium-90 is increasingly recognized for treating hepatocellular carcinoma (HCC) in various stages.
2

Personalized dosimetry significantly enhances treatment outcomes, improving overall survival and objective response rates in HCC patients.
3

The study evaluated the efficacy of a threshold dose in patients with early to advanced-stage HCC treated with resin microspheres.
4

A total of 64 patients diagnosed with HCC underwent TARE with 90Y resin microspheres, following ethical standards and informed consent.
5

The study utilized advanced imaging techniques to assess tumor characteristics and ensure accurate dosimetry for optimal treatment planning.

European Radiology (Springer)

by Ettore di Gaeta, Makoto Taninokuchi Tomassoni, Francesca Calabrese, Giovanni Matassa, Annarita Savi, Carla Canevari, Patrizia Magnani, Giovanna Pepe, Stephanie Steidler, Francesca Ratti, Federica Cipriani, Margherita Rimini, Andrea Casadei-Gardini, Lorenzo Braccischi, Maria Adriana Cocozza, Lidia Strigari, Giuseppe Della Gala, Arber Golemi, Elisa Lodi Rizzini, Stefano Fanti, Matteo Cescon, Matteo Serenari, Fabio Piscaglia, Maria Cristina Morelli, Arturo Chiti, Cristina Mosconi, Francesco De Cobelli
April 28, 2026

1